Greetings, ladies and gentlemen, and welcome to the STRATA Skin Sciences third quarter 2022 earnings conference call. At this time, all participants are on a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Ms. Nicole Jones, Investor Relations. Thank you. Please go ahead.
Thank you, and good afternoon, everyone. Joining me today are Bob Moccia, Chief Executive Officer, and Chris Lesovitz, Chief Financial Officer. Earlier today, STRATA released financial results for the quarter ended September 30th, 2022. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that do not relate to matters of historical fact or relate to expectations or predictions of future events, results or performance are forward-looking statements.
All forward-looking statements, including without limitation those relating to our operating trends and future financial performance, are based upon our current estimates and various assumptions. These statements involve several risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our public filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31st, 2021. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 9th, 2022.
STRATA disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. Also during this presentation, we refer to domestic gross recurring billings, which is a Non-GAAP financial measure. A reconciliation of this Non-GAAP financial measure to the most recently comparable GAAP financial measure is available in the company's earnings release for the third fiscal quarter ended September 30th, 2022, which is accessible on the SEC's website and posted on the Investor Relations page of STRATA's website at www.strataskinsciences.com. I will now turn the call over to Bob.
Thank you, Nicole. We are really excited to announce very strong revenues of $9.4 million for the period ending September 30th, 2022, representing 22% year-over-year growth driven by record XTRAC sales. We have remained acutely focused on the commercial execution and positioning the company for accelerated growth over the coming quarters. We remain targeted in our sales approach and are focused on closing the loop between our direct-to-consumer advertising efforts and the prescribing dermatologists, which we believe has set the stage for our success this quarter. During Q3, we successfully introduced our new product, TheraClearX, for mild to moderate acne. We are enthusiastic about entering into this $5.5 billion acne treatment market, and we believe our product has the potential to make a meaningful impact for those who suffer from acne.
The device utilizes vacuum extraction with light therapy to clear out the occluded pores while reducing sebum or oil production simultaneously. Importantly, TheraClearX delivers STRATA an exciting new commercial opportunity, growth opportunity whereby we have the ability to sell through our well-established partnership program. Contributing to our record sales this quarter was our focus on our targeted therapy messaging, increasing equipment sales in our international markets, and key opinion leader engagement. In our international markets, we have remained flexible in our offerings, shifting to more equipment sales. As we saw this quarter, what we projected going forward is that our international revenue will largely come from capital equipment sales. STRATA has continued to invest in direct-to-consumer, also known as DTC marketing, and direct to dermatology, dermatologist marketing to ultimately drive awareness, adoption, and utilization of XTRAC.
Our approach to DTC has become more focused as we rely on analytics to drive our tactics and strategy to drive decisions around our marketing efforts. In August, Ladenburg Thalmann hosted a key opinion leader or KOL event with Dr. Benjamin Lockshin, MD, FAAD for STRATA as part of its healthcare symposia series. Dr. Lockshin is a director of the clinical trials center at Dermatology Associates and has been a board-certified dermatologist for over 18 years. He also serves as an assistant professor at Georgetown University. During Dr. Lockshin's presentation, he highlighted XTRAC as a safe and cost-effective option for patients suffering from chronic skin conditions like psoriasis and vitiligo. He discussed XTRAC's place as a non-pharmaceutical approach to manage chronic diseases and how the device can be used across the spectrum of disease severity, from monotherapy to combination therapy.
We would like to thank Ladenburg Thalmann and Dr. Lockshin for their time and efforts in hosting this KOL event. Turning now to XTRAC. Earlier this year, we debuted XTRAC Momentum, which has a smaller, sleeker footprint and allows for faster procedure times. We remain enthusiastic about our rollout of Momentum as it represents the latest in excimer laser technology and provides an improved treatment experience for physicians and patients alike. As of September 30th, 2022, there are 899 XTRAC systems placed in dermatologist offices in the United States. An increase from 890 units placed in the period ending December 31st, 2021. We continue to be focused on our strategy of refurbishing and redeploying underutilized assets. This effort helps on multiple fronts.
It allows STRATA to reduce costs of goods sold since we are able to utilize the parts from those other machines that have been removed. Additionally, it allows us to better manage our overall supply chain issues as they arise. We believe keeping underutilized machines below 15% will ensure that the machines in the market are being utilized on a minimum level basis. In July, Incyte's Opzelura became the first FDA-approved treatment for vitiligo, a chronic autoimmune condition that causes the skin to lose pigment. With the approval of the first prescription treatment for vitiligo, we believe this could help drive patients into dermatologist's office and demand for XTRAC services as a complement to the prescription treatments for vitiligo.
As a reminder, STRATA acquired the assets of Ra Medical Systems in August of last year, effectively eliminating our major medical equipment competitor and allowing us to market our full business solution to Ra Medical's existing base. The acquisition increased our install base by an additional 400 dermatology practices, accounting for 250 new accounts. Our sales force is aggressively focused on converting Pharos users to the XTRAC partnership model. We are pleased to have converted 10 of the Pharos users to XTRAC partnership this quarter, totaling 67 customers to date who are committed. We are on track with our conversion expectations. As we previously mentioned, conversions are largely dependent on when a Pharos device will need to be serviced, in which at that time, we have the opportunity to convert the customer to the XTRAC partnership model.
In July, we announced the commercial introduction of TheraClearX, our non-invasive in-office treatment targeting the root cause of mild to moderate acne, launching the company into the $5.5 billion acne treatment market. The device combines vacuum technology and broadband light to treat acne. Through our partnership program, dermatologists are able to offer the TheraClearX to patients without the need to purchase expensive equipment. With acne accounting for 20%-25% of dermatological visits, we believe TheraClearX could be a great synergy for the company. Additionally, STRATA is leveraging its national sales force and commercial team to sell through its existing channels. We expect to have several placements by the end of 2022 and execute on our full launch in 2023. With respect to our international operations, we have remained flexible to the strategy which has shifted to more equipment sales.
In this model, devices are sold directly to dermatologists, emphasizing a cash-driven reimbursement approach. As a reminder, we have distribution agreements in Korea, Japan, China, the Middle East and Israel. Furthermore, acne delivers a large international opportunity, which we hope to address with TheraClearX device. With our focus on international operations, we will believe we will continue to see meaningful growth into the future. With that, I would like to now turn the call over to Chris to discuss the financials. Chris?
Thank you, Bob. Revenues for the third quarter of 2022 were $9.4 million, a 22% increase over the third quarter of 2021. Our third quarter revenue was driven by strong international equipment sales. Non-GAAP adjusted EBITDA was $1.1 million, as compared to $900,000 for the third quarter of 2021. Equipment and revenues for the third quarter were $3.6 million, a 78% increase as compared to $2 million for the third quarter of 2021. Recurring revenues in the third quarter were $5.8 million as compared to $5.7 million for the third quarter of 2021. Non-GAAP gross domestic recurring billings was $5.5 million, a 5% decrease as compared to $5.8 million in the third quarter of 2021.
Overall, gross profit for the third quarter was $5.8 million or 61.6% of revenues as compared to $5.4 million or 69.7% of revenues for the third quarter of 2021. The lower gross margin in the quarter was primarily due to the increase in intangible amortization expenses associated with our recent asset acquisitions of TheraClear and Pharos. Excluding amortization, gross margin was 67% in Q3 of 2022 versus 71.6% in Q3 of 2021. The decrease in gross profit percentage was primarily the result of the product mix, with higher sales of dermatology procedures equipment, which has a lower margin than dermatology recurring procedures. Looking ahead, we continue to expect to see gross margin improvement throughout the remainder of 2022.
Operating expenses were $6.6 million, an increase of 12.7% compared to $5.8 million in the third quarter of 2021. The increase reflects investments in our commercial strategy, including higher direct-to-dermatologist marketing, professional relations activities, various expenses related to the launch of TheraClearX, increased employee-related expenses, and higher consulting service costs. Net loss for the third quarter of 2022 was $1 million, or a loss of $0.03 per basic and diluted common share, as compared to the net loss for the third quarter of 2021 of $500,000, or a loss of $0.02 per basic and diluted common share. At September 30th, 2022, cash and cash equivalents was $8.8 million, as compared to $10 million at June 30, 2022.
Now, turning to our full year guidance we laid out in the beginning of the year. We continue to expect full year 2022 revenues to be in the range of $33 million-$35 million. I will now turn the call over to Bob for his closing remarks. Bob?
As we look at the remainder of the year, we believe there are a few catalysts that will continue to drive revenues. We project TheraClear X to be a significant contributor to our revenues in 2023. To reiterate, we plan on utilizing our already existing sales force to market the device. As dermatologists look for non-prescription complementary treatment for acne, we are confident that TheraClear X could provide the results and clinical benefit necessary. As we mentioned earlier, we launched XTRAC Momentum for our major customers. The device's improved design and increased throughput will allow for treatments to be completed quicker, which could drive increased utilization. Over the past year, STRATA has aggressively implemented an initiative where underutilized machines were moved and redeployed with the goal to reduce the underutilization machines to 15%.
By focusing on this strategy, we were able to manage costs and potential supply chain issues. When looking towards the international markets, our flexible sales model has allowed us to shift more towards equipment sales. By this measure, the international sales channels are making a meaningful impact on our revenues, which we plan to continue for the remainder of the year and beyond. Our acquisition of Ra Medical Systems will also contribute to our revenue growth as we aim to convert Ra users to XTRAC as devices need service, servicing or repair. The XTRAC partnership model is ideal for dermatologists and their practices as it does not require the purchase of capital-intensive equipment. The asset-light model allows dermatologists to remain flexible in their offerings. We remain excited to capitalize on our catalysts and over the remainder of this year.
We will continue to drive XTRAC utilization, grow our presence in our international markets, focus on our direct consumer and direct dermatologist marketing, and continue to roll out TheraClear X, which we believe will meaningfully contribute to growing our top line. I will turn the call over to the operator for a question and answer session. Operator.
Thank you. We will now be conducting a question-and-answer session for analysts. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up the handset before pressing the star keys. Again, for any analyst that would like to ask a question, please press star one on your telephone keypad at this time. The first question today is coming from Jeff Cohen of Ladenburg Thalmann. Please go ahead.
Hi, this is Destiny on for Jeff. Thank you for taking our questions. I'd like to start.
Hi, Destiny.
Hi. Hi. Hope you guys are doing well. I'd like to start first with your commentary around leveraging your DTC campaigns that are existing for XTRAC and that you're leveraging for TheraClear. Can you just give us some additional color on the benefits that that will have in terms of not only growing your top line, getting awareness out to other accounts, but also the benefits in terms of your sales and marketing costs?
Sure. Yeah. As you know, the company's had a lot of success in the past with direct consumer advertising, you know, in particular using social media platforms as well as in-office promotion driven from the offices out to their patients. Had a lot of success with that XTRAC with the partnership model in driving patients into the dermatologist's office for treatments. We think that will work just as well with TheraClear. We haven't completely rolled out a full program for TheraClear at this point. As you know, we're having a controlled launch here since July and really gearing up for our full launch as we move into 2023. We do see the opportunity to develop in-office materials, waiting room type materials, brochures that the patients can bring home.
We'll be utilizing social media as well for TheraClear, you know, as part of our overall DTC marketing plan for 2023. As that relates to our sales and marketing efforts, you know, it really is I think I've talked about it before, Destiny. It's in my mind's closing the loop. We'll follow up that with also direct to dermatologist marketing. We wanna make sure that when we do send patients into the dermatologist office, that the provider is, you know, sure that XTRAC or TheraClear is the right choice for that patient. That requires not only our marketing and professional relations activities, but our sales force in there delivering the right message to our providers so that they feel confident in prescribing XTRAC or TheraClear for their patients. Does that answer your question?
It definitely does. Thank you for that.
Sure.
I guess I'd like to transition, like to transition towards your commentary around vitiligo. We enjoyed hosting Dr. Lockshin for our investor event, and when he was discussing this new drug that, you know, recently launched, he was discussing that there could be opportunity for Strata to also benefit from that. I heard you discuss that briefly in your prepared remarks. I'm just wondering if you can speak a little bit more to that, and if there are any trends you're seeing early on.
Sure. Absolutely. There hasn't been, as you know, you probably know, anything really approved for the indication vitiligo for a long time, drug or device for that matter. XTRAC is one of the few medical treatments that is available for vitiligo. The approval of Opzelura, we believe, is gonna probably cause a lot of vitiligo patients who haven't sought treatment for a while to return to their dermatologist to see what this is all about. As Dr. Lockshin said on the interview you had with him, I think, you know, not only will that in additional patient load coming into the dermatologist be good for XTRAC, but there is some anecdotal discussion out there between KOLs that the drug might work better with light.
Obviously, XTRAC is a light therapy, a targeted therapy, very effective in the use on vitiligo. You know, we believe that, as dermatologists get more experience with Opzelura, they may incorporate light therapy or XTRAC into that treatment regimen. I think that's exciting for us and, you know, we've already armed our sales force with information around that and, you know, marketing materials to promote that message.
Okay, got it. Thank you. Lastly for us, can we just discuss your OUS strategy a bit more and more specifically around the TheraClear device? Thank you for taking our questions.
Sure. Thanks, Destiny. Yeah. I think, you know, as you know, earlier this year, we started to transition a little bit more to capital equipment sales OUS. We do still have a placement model out there. We have a number of placements in Asia. But we did get feedback from some of our distributors that they thought that they could be more effective in actually selling capital equipment in some of the countries. We wanted to be flexible with our distributors. They have boots on the ground and figure that, you know, they know those markets better than we do. We did give them that flexibility, and it's really paid off for us.
You know, particularly if you remember last quarter, we had a $1 million sale in China that was, you know, very helpful for Q2 as well as for the overall year. It continues going forward. We're seeing more and more of our partners looking to purchase machines and sell them in their countries versus the placement. That's worked very well, and we believe that's gonna be similar with TheraClear. We think that we'll, you know, when we start to launch TheraClear in other countries, particularly the Asian countries as well as we think there's an opportunity in Latin America, they'll probably be mainly capital equipment sales. It's the device is not as expensive as an XTRAC or a VTRAC for that matter.
I think we will, you know, we'll probably see more of our partners looking to purchase the TheraClear from us than any kind of placement model.
Got it. All right. Thank you for taking our questions. I'll jump back in queue.
Thanks, Destiny.
Thank you. The next question is coming from Suraj Kalia of Oppenheimer. Please go ahead.
Good afternoon, Bob and Chris. This is actually Mike on for Suraj.
Hey, Mike. How you doing?
Good, Bob. Thanks for taking our questions. Wanted to start by asking, how's the utilization in average revs per system, especially if you can comment on, you know, higher volume accounts versus lower volume accounts. I don't know if you gave, you know, any of the high volume account metrics that I think you've shared in the past, you know, around number of accounts, you know, dollars of revs, percent of revs, that kind of thing.
Yeah, we did it. You know, as you know from last quarter, we have around 200 high volume accounts. That number doesn't fluctuate a whole heck of a lot. They're generating about 50%, you know, maybe a little bit over 50% of our overall revenue. You know, they continue to be, you know, real drivers of the business. They seem to have overcome some of the operational issues that we're seeing in some of our, you know, more middle accounts, if you will. You know, we've talked about a lot this year. There's a lot of staffing issues out there. We know that a lot of dermatologists have sold their practices to private equity.
I think, you know, post-COVID, there's been a lot of changes in the dermatology landscape, and we've done a good job navigating through that. You know, the high volume customers in particular continue to really drive our business.
Okay. That makes sense, Bob. Thanks. You know, turning to the consumer, in this current environment, are you seeing any changes in consumer behavior, you know, any impact on their session completion rates, that sort of thing?
No, I think the patients have come back really strong. I mean, you know, in talking to dermatologists that are in private practice, you know, they have long waiting lists of patients and long waits for appointments. The number of patients is not an issue. Again, you know, staffing has been the real problem operationally. You know, they've had a lot of turnover, and hiring has been a problem just like, you know, in any other industry. So that's been the real kinda headwind that we've seen all year long. We're hoping that, you know, it's really starting to go in the other direction now.
you know, we're expecting a strong Q4, so I think those things, you know, some of those issues will start to take care of themselves. I mean, that's really the only thing that I would say has been a headwind for us. As far as patients go, the patients have come back very strong.
Okay. That's great to hear. You said you expect a strong 4Q. Any, you know, color you would offer as to the performance either on the top line or the gross margin line, you know, relative to 3Q as we look at the balance of the year. Obviously, you reaffirmed your guide for the year despite the nice beat today.
Yep. I'll let Chris handle that one.
Yeah, sure. I mean, you can expect the margins to still increase as compared to prior three quarters here. With that being said, the recurring revenue historically, you'll see Q4 has always been the best quarter for us, and we're anticipating that to occur again. Equipment-wise, international, you know, historically, Q4 has always dipped a little bit, so, you know, we're anticipating the same there, but we're expecting another strong quarter and another strong recurring revenue quarter.
Great.
Yeah, Mike, just to add to that, I mean, you know, as you know, you know, psoriasis is the majority of our usage in the United States for XTRAC. You know, as the weather gets cooler, that's when psoriasis starts to flare up. You know, we always see the fourth quarter being very, very strong for that reason and, you know, no reason to believe it won't be this time around as well.
Okay. That's all really helpful. Thanks, guys.
Sure.
Once again, if there's any analyst that would like to ask a question, please press star one on their telephone keypad at this time. We'll pause for any additional questions. We're showing no additional questions in queue at this time. We'd like to turn the floor back over to Mr. Moccia.
Thank you again for joining us for the third quarter earnings call. We look forward to updating you on our continued progress. Everybody have a good evening.
Ladies and gentlemen, thank you for your participation. This concludes today's event. You may disconnect your lines at this time and enjoy the rest of your evening.